[Recombinant factor VIIa (eptacog alfa): a new therapeutic option for patients with severe bleeding disorder due to inhibitory antibodies against a coagulation factor].
In 2 patients with severe haemorrhage (a 63-year-old man with haemophilia A (the factor VIII level was 29%) and a 44-year-old woman), of an inhibitory antibody against factor VIII was diagnosed. The development of recombinant factor VIIa (eptacog alpha) has made available a new therapeutic option for patients with an inhibitory antibody against a coagulation factor. Both patients were treated successfully with the new factor after other forms of treatment had failed. The new concept of the coagulation cascade on which the treatment with eptacog alpha is based assumes that the lack of an amplifying loop in the coagulation which takes place via factor IX (in combination with factor VIII) can be compensated by extra stimulation of the principal route (tissue factor-factor VIIa --> factor X) by pharmacological amounts of factor VIIa.
Turkstra
F
F
Academisch Medisch Centrum/Universiteit van Amsterdam.
Levi
M
M
Koopman
M M
MM
Wester
J P
JP
Stoutenbeek
C P
CP
Briët
E
E
D000328:Adult; D000906:Antibodies / Q000032:analysis; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D005169:Factor VIII / Q000276:immunology*; D015942:Factor VIIa / Q000008:administration & dosage*; D005260:Female; D006467:Hemophilia A / Q000276:immunology*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000906:Antibodies; D011994:Recombinant Proteins; D005169:Factor VIII; D015942:Factor VIIa